{
  "domain": "immunology",
  "version": "0.1.0",
  "description": "Quantitative priors for immune cell dynamics, cytokine signaling, antibody kinetics, and inflammation",
  "priors": [
    {
      "param": "IgG_serum_concentration",
      "value": [7, 16],
      "unit": "mg/mL",
      "type": 0,
      "source": "Standard clinical reference range, adult serum IgG"
    },
    {
      "param": "IgG_half_life",
      "value": 21,
      "unit": "days",
      "type": 0,
      "source": "Waldmann & Strober 1969, IgG serum half-life"
    },
    {
      "param": "TNFalpha_serum_healthy",
      "value": [0, 8.1],
      "unit": "pg/mL",
      "type": 0,
      "source": "Standard clinical reference, TNF-alpha normal range"
    },
    {
      "param": "IL6_serum_healthy",
      "value": [0, 7],
      "unit": "pg/mL",
      "type": 0,
      "source": "Standard clinical reference, IL-6 normal range"
    },
    {
      "param": "CRP_inflammation_threshold",
      "value": 10,
      "unit": "mg/L",
      "type": 0,
      "source": "Clinical cutoff: CRP > 10 mg/L indicates significant inflammation"
    },
    {
      "param": "T_cell_doubling_time_activated",
      "value": [8, 12],
      "unit": "hours",
      "type": 1,
      "source": "Yoon et al. 2010, activated T cell proliferation rate"
    },
    {
      "param": "NK_cell_killing_rate",
      "value": [2, 6],
      "unit": "targets/NK/day",
      "type": 1,
      "source": "Bhat & Bheemshetty 2016, NK cell cytotoxicity rate"
    },
    {
      "param": "antibody_affinity_maturation_fold",
      "value": [10, 1000],
      "unit": "fold_increase",
      "type": 1,
      "source": "Victora & Nussenzweig 2012, affinity increase during germinal center reaction"
    },
    {
      "param": "PD1_PDL1_Kd",
      "value": 8.2,
      "unit": "uM",
      "type": 1,
      "source": "Cheng et al. 2013, PD-1/PD-L1 binding affinity"
    },
    {
      "param": "checkpoint_inhibitor_response_rate",
      "value": [0.15, 0.40],
      "unit": "fraction",
      "type": 1,
      "source": "Ribas & Wolchok 2018, anti-PD-1 objective response rates across cancer types"
    },
    {
      "param": "cytokine_storm_IL6_threshold",
      "value": 100,
      "unit": "pg/mL",
      "type": 1,
      "source": "Chen et al. 2020, IL-6 threshold for cytokine release syndrome"
    }
  ]
}
